Please login to the form below

Not currently logged in
Email:
Password:

NTDT

This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical

Latest news

  • CHMP backs Novartis' Bexsero, Exjade CHMP backs Novartis' Bexsero, Exjade

    It was approved in Europe in March, 2010. Thalassaemia candidate. Meanwhile, the CHMP also gave its backing to Novartis' Exjade (deferasirox) as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, ... Clinical trials have shown

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics